Get the Stockscreener App
3.07
4.36%
-0.14
After Hours:
3.15
0.08
+2.61%
Sonoma Pharmaceuticals Inc stock is traded at $3.07, with a volume of 109.88K.
It is down -4.36% in the last 24 hours and down -6.97% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$3.21
Open:
$3.16
24h Volume:
109.88K
Relative Volume:
0.52
Market Cap:
$3.32M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-2.0197
EPS:
-1.52
Net Cash Flow:
$-5.20M
1W Performance:
-3.46%
1M Performance:
-6.97%
6M Performance:
-7.70%
1Y Performance:
-80.11%
1-Day Range:
$3.07
$3.33
1-Week Range:
$3.07
$3.4499
52-Week Range:
$2.318
$16.00
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
SONO’s latest rating updates from top analysts. - Knox Daily
Top investors say Sonos Inc (SONO) ticks everything they need - SETE News
15,500 Shares in Sonoco Products (NYSE:SON) Acquired by Skandinaviska Enskilda Banken AB publ - Defense World
Federated Hermes Inc. Sells 466 Shares of Sonoco Products (NYSE:SON) - Defense World
Intubation Tubes Market Report Details Growth Drivers, Opportunities, Share Report And Forecast To 2033 - WhaTech
Hypertrophic And Keloid Scar Treatment Market Advancements Highlighted by Size, Growth,Outlook Report 2033 - WhaTech
Scar Treatment Global Market Report 2024: Growth Drivers and Dynamics 2033 - WhaTech
Sei Investments Co. Has $75.60 Million Position in Sonoco Products (NYSE:SON) - Defense World
Ameritas Investment Partners Inc. Reduces Stock Position in Sonoco Products (NYSE:SON) - Defense World
Sonoma Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - MSN
AE Wealth Management LLC Buys 12,401 Shares of Sonoco Products (NYSE:SON) - Defense World
Richardson Financial Services Inc. Sells 1,295 Shares of Sonoco Products (NYSE:SON) - Defense World
China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma Pharmaceuticals Inc. (SNOA)’s Day in Review: Closing at 3.83, Down by -10.93 - The Dwinnex
Financial Fitness Check: Examining Sonos Inc (SONO)’s Key Ratios - The Dwinnex
Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Pass Above 200-Day Moving Average of $0.33 - MarketBeat
Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Cross Above Two Hundred Day Moving Average of $0.33 - Defense World
Sonoma Pharmaceuticals regains Nasdaq compliance - Investing.com
MQS Management LLC Purchases 7,448 Shares of Sonoco Products (NYSE:SON) - Defense World
Sonoma Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule - StockTitan
There is no way Sonoma Pharmaceuticals Inc. (SNOA) can keep these numbers up - SETE News
SNOA’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Sonoma Pharmaceuticals gets FDA nod for OTC eye care product - Investing.com
Another Delaware Publicly Traded Company Proposes A Nevada Move - The National Law Review
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution - AccessWire
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution - Marketscreener.com
Hypochlorous Acid Market To Develop Speedily With CAGR Of 4.1% By 2033 - Chemical Market Reports
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Drop in Short Interest - MarketBeat
Sonoma Pharmaceuticals expands eye care line with EMC Pharma - Investing.com India
Sonoma Pharmaceuticals expands eye care line with EMC Pharma - Investing.com
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line - AccessWire
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line - Morningstar
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration - Business Wire
Scar Treatment Market Huge Growth in Future Scope 2024-2031 | - openPR
Market Resilience: Sonoma Pharmaceuticals Inc. (SNOA) Finishes Strong at 3.30, Up 3.55 - The Dwinnex
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Passes Above 200-Day Moving Average of $0.23 - MarketBeat
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200 Day Moving Average of $0.23 - Defense World
Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins - Stocks Telegraph
Why Sonoma Pharmaceuticals (SNOA) Stock Is Moving - MSN
Sonoma Pharmaceuticals announces 1-for-20 reverse stock split By Investing.com - Investing.com Australia
Prepare Yourself for Liftoff: Sonoma Pharmaceuticals Inc. (SNOA) - SETE News
Why Sonoma Pharmaceuticals (SNOA) Stock Is Moving - Benzinga
The SNOA Stock Puzzle: Unraveling Sonoma Pharmaceuticals Inc.’s Fluctuating Performance - The InvestChronicle
Sonoma Pharmaceuticals to Effect 1-for-20 Reverse Stock Split - Marketscreener.com
Sonoma Pharmaceuticals announces 1-for-20 reverse stock split - Investing.com
Sonoma Pharmaceuticals Stockholders Decide on Key Governance Issues - TipRanks
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock - AccessWire
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock - Yahoo Finance
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower - Simply Wall St
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):